IDEXX Laboratories stock holds firm as valuation stays rich

Published on 09/15/2026 at 23:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock closed at USD 509.56 on September 14, 2026, with revenue rising from USD 3.22 billion to USD 4.30 billion over recent years. Free cash flow reached USD 1.06 billion, underlining the diagnostics group’s strong cash generation.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories stock (ISIN US45168D1046) finished at USD 509.56 as of September 14, 2026, highlighting the company’s position as a high-valuation diagnostics player with robust cash generation per a recent long-term stock overview dated September 15, 2026.Investing.com The same analysis underscores that IDEXX’s premium pricing is supported by solid fundamentals in veterinary and water diagnostics.

Revenue and cash flow trends support premium valuation

According to Investing.com on September 15, 2026, IDEXX Laboratories has grown its revenue from USD 3.22 billion to USD 4.30 billion over recent fiscal years, illustrating steady expansion in its diagnostics franchise. That increase of USD 1.08 billion represents roughly 33.5 percent growth, a pace that underpins investor confidence in the company’s recurring demand model.

The same overview notes that free cash flow reached USD 1.06 billion over the latest measured period, a level that gives IDEXX Laboratories substantial flexibility for investment and potential shareholder returns.Investing.com With revenue of USD 4.30 billion and free cash flow of USD 1.06 billion, the implied free cash flow margin stands near 24.7 percent, an attractive level for a company focused on veterinary and water testing solutions.

Valuation metrics highlight quality and cost

Per the same long-term screen, IDEXX Laboratories stock trades at a price-to-earnings multiple of 35.2 times, signaling that the market is willing to pay a substantial premium for the company’s growth and defensive qualities.Investing.com The same analysis cites a modeled fair value upside of 2.2 percent from the recent closing price, suggesting limited near-term valuation headroom but a solid longer-term quality profile.

In that context, the diagnostics group is characterized as offering defensive quality with premium pricing, driven by recurring demand and high switching costs in veterinary diagnostics.Investing.com For investors, the combination of strong free cash flow and a high earnings multiple means the stock remains a quality holding, albeit one where expectations are already elevated.

Stock level and market context

Closing at USD 509.56 on September 14, 2026, IDEXX Laboratories stock sits close to the fair value estimate cited in the long-term screen, with the indicated upside of 2.2 percent pointing to a market that already prices in much of the company’s growth story.Investing.com The screen notes that a recent one-year share price decline has modestly improved the entry setup, even though the stock still trades at a premium multiple.

Against this backdrop, the key question for holders of IDEXX Laboratories stock is whether the company can sustain double-digit revenue growth and high cash flow margins to justify the 35.2 times earnings valuation over the coming years. The core franchises in companion animal and water testing, which generate recurring diagnostics revenues, remain central to that long-term thesis.Investing.com